Navicixizumab (Anti-DLL4 & VEGF)
Product Specifications
CAS Number
1638338-43-8
Synonyms
OMP 305B83
SKU
C00920-1mg
Target
VEGFR
Applications
Protein Tyrosine Kinase
Additionnal Information
Navicixizumab is a bispecific monoclonal antibody targeting DLL4 and VEGF, with potential anti-angiogenic and antineoplastic activities. It has shown antitumor effects in multiple cancer types, with the most promising results in ovarian cancer. M.W 146.17 kDa
Storage Conditions
-80°C (avoid freeze-thaw cycles)
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
